Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance

Document Type: Original Article


1 Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran


3 Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

4 Proteomics laboratory, Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

5 Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran


Objective(s): Chemoresistance remains the main causes of treatment failure and mortality in cancer patients. There is an urgent need to investigate novel approaches to improve current therapeutic modalities and increase cancer patients' survival. Induction of drug efflux due to overexpression of                  P-glycoproteins is considered as an important leading cause of multidrug resistance. In this study, we investigated the role of combination treatments of docetaxel and vinblastine in overcoming                             P-glycoprotein mediated inhibition of apoptosis and induction of cell proliferation in human non-small cell lung carcinoma cells.
Materials and Methods:Cell proliferation and apoptosis were assessed using MTT assay and DAPI staining, respectively. P-glycoprotein expression was evaluated in gene and protein levels by Real-time RT-PCR and Western blot analysis, respectively.
Results: Combination treatment of the cells with docetaxel and vinblastine decreased the IC50 values for docetaxel from (30±3.1) to (15±2.6) nM and for vinblastine from (30±5.9) to (5±5.6) nM (P≤0.05).               P-glycoprotein mRNA expression level showed a significant up-regulation in the cells incubated with each drug alone (P≤0.001). Incubation of the cells with combined concentrations of both agents neutralized P-glycoprotein overexpression (P≤0.05). Adding verapamil, a P-glycoprotein inhibitor caused a further increase in the percentage of apoptotic cells when the cells were treated with both agents. 
Conclusion:Our results suggest that combination therapy along with P-glycoprotein inhibition can be considered as a novel approach to improve the efficacy of chemotherapeutics in cancer patients with high P-glycoprotein expression.


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29.

2. Pallis AG. A review of treatment in non-small-cell lung cancer. Eur Oncol Haematol 2011; 7:27-31.

3. Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, et al. Second-line paclitaxel/carboplatin versus vinorelbine/carbo-platin in patients who have advanced non–small-cell lung cancer pretreated with non–platinum-based chemotherapy: a multicenter randomized phase II study. Clin Lung Cancer 2011; 12:100-105.

4. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006; 130:1211-1219.

5. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83:288-291.

6. Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents 2002; 2:55-70.

7. Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002; 7:13-19.

8. Ghanbari P, Mohseni M, Tabasinezhad M, Yousefi B, Saei AA, Sharifi S, et al. Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol 2014; 174:667-681.

9. Samadi N, Ghanbari P, Mohseni M, Tabasinezhad M, Sharifi S, Nazemieh H, et al. Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells. J Cancer Res Ther 2014; 10:715.

10. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-681.

11. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract 2012; 2012.

12. Nourbakhsh M, Jaafari MR, Lage H, Abnous K. Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci 2015; 18:385.

13. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65:95-106.

14. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32:S3-8.

15. Komeili-Movahhed T, Fouladdel S, Barzegar E, Atashpour S, Ghahremani MH, Ostad SN, et al. PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy. Iran J Basic Med Sci 2015; 18:472.

16. Sharifi S, Barar J, Hejazi MS, Samadi N. Roles of the bcl-2/bax ratio, caspase-8 and 9 in resistance of breast cancer cells to Paclitaxel. Asian Pac J Cancer Prev 2014; 15:8617-8622.

17. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1. Annu Rev Pharmacool Toxicol 1999; 39:361-398.

18. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22:7369-7375.

19. Eastman A, Schulte N. Enhanced DNA repair as                a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 1988; 27:4730-4734.

20. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100:1282-1293.

21. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5:662-668.

22. Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M, et al. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev 2013; 15:5311-5316.

23. Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y, et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. Br J Cancer 1996; 74:1929-1934.

24. Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers. Br J Cancer 1991; 64:700.

25. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265-283.

26. Samadi N, Gaetano C, Goping I, Brindley D. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2008; 28:1028-1039.

27. Samadi N, Bekele RT, Goping IS, Schang LM, Brindley DN. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PloS One 2011; 6:e20608.

28. Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 2011; 17:3193-203.

29. Chiu L-Y, Ko J-L, Lee Y-J, Yang T-Y, Tee Y-T, Sheu G-T. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of< i> ABCB1</i> expression in human lung cancer cell lines. Toxicol Lett 2010; 192:408-418.

30. Ross DD, Wooten P, Sridhara R, Ordonez J, Lee EJ, Schiffer C. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993; 82:1288-99.

31. Ferrao PT, Frost MJ, Siah S-P, Ashman LK. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003; 102:4499-4503.

32. Herzog C, Tsokos M, Bates S, Fojo A. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 1993; 268:2946-2952.

33. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785:96-132.

34. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009; 8:21.

35. Samadi N, Bekele R, Capatos D, Venkatraman G, Sariahmetoglu M, Brindley DN. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 2011; 93:61-70.

36. Bell DR, Gerlach J, Kartner N, Buick R, Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985; 3:311-315.

37. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, et al. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 2007; 173:1-9.

38. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010; 31:358-365.

39. Tsakalozou E, Eckman AM, Bae Y. Combination effects of docetaxel and doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int 2012; 2012.

40. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 2002; 8:904-912.

41. Nelli F, Naso G, De Pasquale Ceratti A, Saltarelli R, D'auria G, Lugini A, et al. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial. J Chemother 2004; 16:392-9.

42. Schmittel A, Siehl JM, Schulze M, Schulze K, Thiel E, Keilholz U. Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients. Anticancer Res 2005; 25:1333-1336.

43. Dimitroulis J, Toubis M, Antoniou D, Marosis C, Armenaki U, Stathopoulos G, et al. Alternate paclitaxel-gemcitabine and paclitaxel-vinorelbine biweekly administration in non-small cell lung cancer patients: A phase II study. Anticancer Res 2006; 26:1397-1402.

44. Tester W, Ackler J, Tijani L, Leighton J. Phase I/II
study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J 2006; 12:299-304.

45. Chin K-V, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1990; 1:361-365.

46. Kohno K, Sato S-i, Takano H, Matsuo K-i, Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 1989; 165:1415-1421.

47. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-162.

48. Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol 1987; 36:2879-2887.

49. Meyers M. Protein phosphorylation in multidrug resistant Chinese hamster cells. Cancer Commun 1989; 1:233.

50. Hofsli E, Nissen-Meyer J. Reversal of multidrug resistance by lipophilic drugs. Cancer Res 1990; 50:3997-4002.

51. Karwatsky J, Lincoln MC, Georges E. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 2003; 42:12163-12173.

52. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn‐Langguth H, Wunderli‐Allenspach H, et al. P‐glycoprotein (P‐gp) mediated efflux in Caco‐2 cell monolayers: The influence of culturing conditions and drug exposure on P‐gp expression levels. J Pharm Sci 1998; 87:757-762.

53. Muller C, Bailly JD, Goubin F, Laredo J, Jaffrézou JP, Bordier C, et al. Verapamil decreases P‐glycoprotein expression in multidrug‐resistant human leukemic cell lines. Int J Cancer 1994; 56:749-754.

54. Osman A-MM, Mohamad MA, Abdel-Wahab A-HA, Sayed-Ahmad MM. Modulation by verapamil of doxorubicin induced expression of multidrug resistance gene (mdr-1/P-glycoprotein) in murine tumour cells. J Egypt Natl Cancer Inst 2000; 12:221-227.

55. Al-Shabanah O, Osman A-M, Al-Harbi M, Al-Bekairi A, Al-Gharably N, Aziz S. Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells. Chemotherapy 2009; 41:368-377.

56. Hori Y, Kawamoto K, Yamazaki N, Kumazawa H, Yamashita T, Kumazawa T. Establishment of a cisplatin-resistant KB cell line and its characterization. Acta Otolaryngol Suppl 1993; 113:142-148.